Background: The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite
The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite index to assess disease activity in axial spondyloarthritis (SpA). [1] [2] [3] It combines five single disease activity variables in such a manner that it optimally conveys information, resulting in one single score with better truth (validity), enhanced discriminative capacity and improved ability to detect change as compared to separate variables. [1] [2] [3] [4] [5] ASDAS cut-offs have been developed to define disease activity states and response criteria to treatment. [2] ASDAS has been endorsed by the Assessment of SpondyloArthritis international Society (ASAS) and by the Outcome Measures in Rheumatology (OMERACT) study group and validated in various populations worldwide. [5] [6] [7] [8] [9] [10] The ASAS membership has selected the ASDAS containing C-reactive protein (CRP) as the preferred version and the ASDAS containing erythrocyte sedimentation rate (ESR) as the alternative version. [1] [2] [3] The same validated cut-offs apply to both ASDAS-CRP and ASDAS-ESR. [2] The development and validation of the ASDAS was based on values with conventional CRP (cCRP). It was suggested that when the cCRP is below the limit of detection, and high sensitivity CRP (hsCRP) is not available, 50% of the threshold value should be used to calculate ASDAS-CRP. [2] However, neither this recommendation nor the effect of using hsCRP was data driven and requires further testing.
The aims of this study were to investigate the best way to calculate the ASDAS when the cCRP is below the limit of detection, to study the arithmetic influence of low CRP values as obtained by hsCRP in ASDAS-CRP results and to test agreement between different ASDAS formulae.
METHODS

Patients
Baseline data from the Devenir des Spondylarthropathies Indifférenciées Récentes (DESIR) cohort was used. Details of the DESIR cohort have been previously described. [11] Briefly, DESIR is a French prospective, multicenter study of patients with early (<3 years) inflammatory back pain (IBP) suggestive of SpA. A total of 708 patients were included in the DESIR cohort at baseline. For this study, we selected all patients fulfilling the ASAS classification criteria for axial SpA with a cCRP value below the limit of detection and available hsCRP, and we have used baseline assessments only. We used the dataset locked on December 12th, 2011.
ASDAS Calculation
ASDAS-CRP and ASDAS-ESR were calculated based on 5 variables, one of the them being an acute phase reactant (either CRP or ESR) and the other four being patient-reported items, [1, 2] 
RESULTS
Patients' characteristics
A total of 260 patients fulfilled the inclusion criteria. Three patients had missing ASDAS and therefore data from 257 patients was available. Supplementary table 1 shows the demographic and clinical characteristics of the study population. Table 1 shows the level of agreement between ASDAS formulae, both as a continuous and as a categorical (disease activity states) variable. The decision about the optimal CRP threshold value can be done by looking at hypothetical case scenarios (graphically it can already be seen that this threshold should be between 1.5 and 2.5 mg/L). Table 2 using the CRP constant value of 2.5 but inactive disease (ASDAS=1.2) using the CRP constant value of 2: again, clinically the last scenario makes more sense.
Agreement between ASDAS formulae
Effect of low CRP values in ASDAS-CRP results
Supplementary
These two examples favour the use of the constant value of 2mg/L rather than 1.5 or 2.5mg/L as the ideal imputation strategy for very low CRP. 
DISCUSSION
The availability of cCRP and hsCRP determinations in the DESIR cohort allowed us to perform this analysis in a large population of patients with early IBP fulfilling the ASAS classification criteria for axial SpA. Our study shows that when the cCRP value is below the limit of detection, the value of 2mg/L should be used to calculate ASDAS-CRP. Furthermore, when the hsCRP value is below 2mg/L, the constant value of 2mg/L should also be used to calculate ASDAS-CRP.
We have shown that for very low hsCRP values small differences represent larger steps in the CRP term of the ASDAS formula and therefore larger steps in the total ASDAS-CRP value. The final choice of the best imputation value was made by looking at a matrix of clinical scenarios (table 2) Disagreement between ASDAS-hsCRP and other ASDAS formulae was mainly in lower disease activity states (inactive disease/moderate disease activity), a shift that has less therapeutic implications than the shift between moderate and high/very high disease activity. This is particularly important given recent evidence that the ASDAS cut-off for high disease activity (ASDAS≥2.1) is likely to be the most appropriate ASDAS cut-off to select patients for TNF-blocker treatment, including accumulated evidence supporting the replacement of the commonly used BASDAI selection cut-off of 4 units (0-10 scale) by the ASDAS high disease activity cut-off. [12] [13] [14] One of the limitations of our study is the fact that this is a selected population with early disease. Therefore results might not be generalizable to the entire spectrum of axial SpA patients, in particular to patients with advanced disease/ankylosing spondylitis.
However, the lack of generalizability is unlikely given by the fact that CRP is more frequently elevated in AS than in non-radiographic axial SpA, so the need to substitute cCRP values below the limit of detection or very low hsCRP values will occur more often in early disease than in late disease. [15] ASDAS is increasingly being used as a measure of disease activity in clinical practice, clinical trials and observational studies. [14] This study contributes to further standardization of the ASDAS and to a more homogeneous and reproducible application of this new index. 
